What is insulin resistance?

Insulin resistance occurs when normal amounts of insulin become less effective at moving glucose from the bloodstream into cells (muscle, liver, adipose). To keep blood glucose normal the pancreas secretes more insulin (hyperinsulinaemia). Over time the beta cells may fail to compensate, and glucose levels rise — first to prediabetes, then to type 2 diabetes in many cases. Authoritative patient summaries (Harvard Health, Mayo Clinic) describe this sequence and its health implications. ([health.harvard.edu](https://www.health.harvard.edu/topics/insulin-resistance?utm_source=openai))

How many Canadians are "at risk" — interpreting "1 in 3"

The phrase "1 in 3" comes from Diabetes Canada’s national estimates and models combining diagnosed diabetes and estimated prediabetes — reflecting both diagnosed and undiagnosed individuals at elevated risk. This is a population‑level message meant to highlight the combined burden of diabetes + prediabetes. ([diabetes.ca](https://www.diabetes.ca/media-room/press-releases/one-in-three-canadians-is-living-with-diabetes-or-prediabetes%2C-yet-knowledge-of-risk-and-complicatio?form=donate&s_appealCode=1058-350%3A+11984+%2F+30110+%2F+DM-NAT+ONLINE+Landing+Page+2025+%2F+Online+donation&utm_source=openai))

But method matters. Measured data from the Canadian Health Measures Survey (A1C) find lower direct prediabetes prevalence (~6.0–6.3%) when using A1C criteria, while Statistics Canada’s analysis of metabolic syndrome (MetS) reports about 26% prevalence (2016–2019) — MetS is a cluster of risk factors closely linked with insulin resistance. Differences reflect how prediabetes/insulin resistance are defined and measured. ([health-infobase.canada.ca](https://health-infobase.canada.ca/diabetes/?utm_source=openai))

How Canada measures glucose and risk (use mmol/L)

  • A1C: In Canada, Diabetes Canada defines prediabetes as A1C 6.0–6.4% and diabetes as A1C ≥6.5%. ([guidelines.diabetes.ca](https://guidelines.diabetes.ca/cpg/chapter4))
  • Fasting plasma glucose (FPG): Diabetes is diagnosed at FPG ≥7.0 mmol/L; values between 5.6 and 6.9 mmol/L require context/OGTT. Use mmol/L units in Canadian communications. ([guidelines.diabetes.ca](https://guidelines.diabetes.ca/cpg/chapter4))
  • OGTT: Useful when FPG/A1C are borderline or when suspicion is high (detects impaired glucose tolerance). ([guidelines.diabetes.ca](https://guidelines.diabetes.ca/cpg/chapter4))

Regional and population variation across Canada

Statistics Canada and CIHI show differences by province and population group: Indigenous peoples, some racialized communities (South Asian, Black), and lower‑income neighbourhoods have higher diabetes burden and complications. Access to primary care, provincial screening protocols, and social determinants affect prevention and outcomes — so local tailoring is essential. ([www150.statcan.gc.ca](https://www150.statcan.gc.ca/n1/pub/82-003-x/2025009/article/00001-eng.htm))

Why early detection and prevention matter

Insulin resistance and elevated glucose increase cardiovascular, renal, and microvascular risks. Diabetes‑related complications drive hospital admissions and high system costs in Canada (CIHI). Early screening, lifestyle intervention and targeted supports reduce progression and complications at both individual and system levels. ([cihi.ca](https://www.cihi.ca/en/equity-in-diabetes-care-a-focus-on-lower-limb-amputation/amputations-signal-opportunities-to-improve-diabetes-care-and-reduce-system-costs?utm_source=openai))

What the evidence says about interventions (ranked: SR/MA > RCT > cohort)

Soluble fibre

A systematic review and meta‑analysis of RCTs showed soluble‑fiber supplementation improved glycaemic control: reductions in HbA1c, fasting plasma glucose (FPG decreased by about 0.8–0.9 mmol/L in some analyses), fasting insulin and HOMA‑IR in people with dysglycaemia. Fibre slows intestinal glucose absorption and modifies gut microbiota — mechanisms relevant to insulin sensitivity. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/33162192/?utm_source=openai))

Time‑restricted eating (TRE) and intermittent fasting

Recent systematic reviews and randomized trials report modest improvements in insulin resistance (HOMA‑IR), fasting insulin and some metabolic markers with TRE compared with control eating patterns; effects are often mediated by weight loss and calorie reduction. TRE regimens vary (e.g., 8‑hour window, or structured protocols such as a 4‑4‑12 pattern) and should be individualized. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/36190980/?utm_source=openai))

Yerba mate / chlorogenic acids

Small RCTs of yerba mate show reductions in fasting glucose and insulin in selected groups; chlorogenic acids (found in mate and coffee) have biological plausibility for improving glucose handling. Larger trials are needed, but these compounds may complement lifestyle strategies. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12319497/?utm_source=openai))

Actionable, Canada‑focused plan — what to do next

  1. Screen: Use A1C and/or FPG — Diabetes Canada recommends screening every 3 years from age 40, earlier if high risk (CANRISK). Follow provincial pathways for lab access or walk‑in clinics/family doctors. ([guidelines.diabetes.ca](https://guidelines.diabetes.ca/cpg/chapter4))
  2. Measure in mmol/L and document A1C (6.0–6.4% = prediabetes; A1C ≥6.5% or FPG ≥7.0 mmol/L = diabetes after confirmation). ([guidelines.diabetes.ca](https://guidelines.diabetes.ca/cpg/chapter4))
  3. Start lifestyle steps: aim for 5–10% weight loss if overweight, 150 min/week moderate activity, increase soluble fibre (oats, legumes, psyllium), consider TRE if appropriate and safe (discuss with provider). Evidence supports glycaemic benefits. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/33162192/?utm_source=openai))
  4. Use Canadian resources: Canada's Food Guide for balanced meals, local provincial preventive services, and Diabetes Canada education programs. Check coverage and referral options by province (Ontario, BC, Alberta, Quebec differences). ([health-infobase.canada.ca](https://health-infobase.canada.ca/diabetes/?utm_source=openai))
  5. Consider supportive supplements/tools with caution: look for Health Canada NPN on natural products, and always check interactions if you take glucose‑lowering medications. Discuss with your family doctor or pharmacist. ([canada.ca](https://www.canada.ca/en/public-health/services/publications/diseases-conditions/framework-diabetes-canada.html?utm_source=openai))

How "Feel Great" fits in (supportive, non‑therapeutic)

Feel Great offers a lifestyle support system combining:

  • Balance — a soluble‑fibre matrix designed to moderate post‑meal glucose (consistent with evidence for soluble fibre reducing FPG and HOMA‑IR). ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/33162192/?utm_source=openai))
  • Unimate — yerba‑mate extract containing chlorogenic acids shown in small trials to lower fasting glucose/insulin in selected participants. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12319497/?utm_source=openai))
  • A 4‑4‑12 intermittent fasting framework — a structured TRE approach aligned with time‑restricted eating research suggesting modest improvements in insulin resistance when adhered to. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/36190980/?utm_source=openai))

These are supportive lifestyle tools, not medicines; they may help some people as part of a broader prevention plan. Always verify product NPNs and discuss with your healthcare team before use.

When to seek immediate medical care

Seek assessment if you have very high glucose readings (A1C ≥6.5% or FPG ≥7.0 mmol/L), typical hyperglycaemia symptoms (extreme thirst, frequent urination, unexplained weight loss), or if you are on glucose‑lowering medicines and change diet/timing to avoid hypoglycaemia. ([guidelines.diabetes.ca](https://guidelines.diabetes.ca/cpg/chapter4))

System‑level implications for Canada

Population‑level prevention (screening, food‑environment policies, equitable access to primary care and culturally‑tailored interventions) can reduce future diabetes incidence and complications — lowering hospitalizations and costly procedures (amputations, dialysis). CIHI and Statistics Canada data support the case for targeted, province‑specific prevention investments. ([cihi.ca](https://www.cihi.ca/en/equity-in-diabetes-care-a-focus-on-lower-limb-amputation/amputations-signal-opportunities-to-improve-diabetes-care-and-reduce-system-costs?utm_source=openai))